Bioventus (BVS) Total Liabilities (2020 - 2026)

Bioventus (BVS) has reported Total Liabilities for 7 consecutive years, with $395.9 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Total Liabilities fell 21.67% year-over-year to $395.9 million; the trailing twelve-month figure through Jun 2026 stood at $395.9 million (down 21.67% YoY), and the FY2025 full-year result was $455.1 million, down 16.09% from the prior year.
• Total Liabilities declined to $395.9 million in Q2 2026 per BVS's latest filing, from $416.3 million in the prior quarter.
• Across five years, Total Liabilities topped out at $1.0 billion in Q4 2022 and bottomed at $395.9 million in Q2 2026.
• Historically, Total Liabilities has averaged $602.6 million across 5 years, with a median of $583.7 million in 2023.
• The sharpest annual moves came in 2022 and 2023: Total Liabilities jumped 140.14% in 2022, then slumped 42.62% in 2023.
• Over 5 years, Total Liabilities stood at $960.4 million in 2022, then plunged by 38.59% to $589.8 million in 2023, then slipped by 8.04% to $542.4 million in 2024, then fell by 16.09% to $455.1 million in 2025, then decreased by 13.0% to $395.9 million in 2026.
• According to Business Quant data, Total Liabilities over the past three periods registered $395.9 million, $416.3 million, and $455.1 million for Q2 2026, Q1 2026, and Q4 2025 respectively.